CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6152 result(s)

Fecal Microbiota Therapy in Canada: Barriers and Facilitators to Access

Last Updated: September 17, 2020
Result type: Reports
Product Line: Environmental Scans
Research Type: Device

Evidence supports the use of fecal microbiota transplant (FMT) for recurrent clostridium difficile (C. difficile) infection. Information on the potential of FMT for treating other conditions, such as inflammatory bowel disease, ulcerative colitis, and Crohn disease, is also emerging. The indications and demand for FMT may increase in future, yet...

  • Project Number: ES0341-000

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: September 16, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: von Willebrand Factor [recombinant]
Indications: von Willebrand disease, adults, treatment and perioperative management

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: New

etonogestrel (Nexplanon)

Last Updated: September 16, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: etonogestrel
Indications: Prevention of pregnancy

  • Brand Name: Nexplanon
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0648-000
  • Project Status: Active
  • Submission Type: New

ozanimod (TBC)

Last Updated: September 15, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ozanimod
Indications: Multiple Sclerosis, relapsing - remitting

  • Brand Name: TBC
  • Manufacturer: Celgene Inc.
  • Project Number: SR0652-000
  • Project Status: Active
  • Submission Type: New